SUPPLEMENTARY INFORMATION
|
|
- Claude Daniel
- 6 years ago
- Views:
Transcription
1 SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: accessed on May 2, 2015). ClinicalTrials. Treatment Phase Patient population N Status gov dentifier NVOLUMAB gemcitabine /cisplatin, pemetrexed /cisplatin, carboplatin /paclitaxel, bevacizumab maintenance, erlotinib or Nivolumab + sunitinib or pazopanib or bevacizumab or vs sunitinib Advanced NSCLC 412 Ongoing NCT Advanced untreated renal cell carcinoma Advanced renal cell carcinoma Previously untreated, advanced or metastatic renal cell carcinoma 175 NCT Ongoing NCT Ongoing NCT Advanced melanoma 160 Ongoing NCT Vaccine (Class Peptides) + Montanide SA 51VG + Resected stage C/ V nivolumab or 85 Ongoing NCT nivolumab Vaccine (Class Peptides) + Montanide SA 51VG + nivolumab Sequential nivolumab and followed by nivolumab pilimumab +/- nivolumab followed by dabrafenib/ trametinib or opposite sequence pilimumab vs. nivolumab vs. nivolumab + Unresectable Stage or V Malignant Unresectable Stage /V Metastatic to the Brain Previously Untreated, Unresectable or Metastatic Advanced BRAF V600 mutation-positive melanoma Previously Untreated Unresectable or Metastatic NCT NCT NCT Ongoing NCT NCT NCT NCT NATURE REVEWS CANCER
2 SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Dabrafenib + trametinib followed by + nivolumab at progression vs. +nivolumab followed by dabrafenib + trametinib at progression or lirilumab (anti-kr antibody) Nivolumab + Urelumab Nivolumab + pilimumab Nivolumab + HPV-16 Vaccination GVAX pancreas vaccine, cyclophosphamide + CRS /- nivolumab Nivolumab vs nivolumab + vs bevacizumab in solid tumours Nivolumab + varlilumab (anti CD27 antibody) Nivolumab + anti-lag-3 monoclonal antibody Expande d access - Advanced BRAFV600 Mutant Untreated, Unresectable or Metastatic Younger Patients With Recurrent or Refractory Solid Tumours or Sarcomas Lymphoma and Multiple Myeloma Advanced/Metastatic Solid Tumours and B-cell Non- Hodgkin Lymphoma Patients With Advanced HV Associated Solid Tumours Patients With HPV-16- Positive ncurable Solid Tumours Recurrent and Metastatic Microsatellite High Colon Cancer Previously Treated Metastatic Pancreatic Adenocarcinoma 300 Ongoing NCT Ongoing NCT Ongoing NCT Ongoing NCT Ongoing NCT NCT NCT Ongoing NCT Ongoing NCT Glioblastoma 440 Ongoing NCT Triple-negative breast cancer, gastric cancer, pancreatic adenocarcinoma, small cell lung cancer and bladder cancer Non-Small Cell Lung Cancer,, Colorectal, Ovarian or Head and Neck Squamous Cell Carcinoma. 410 Ongoing NCT Ongoing NCT Advanced Solid Tumours 168 Ongoing NCT NATURE REVEWS CANCER
3 SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Nivolumab + lirilumab (anti-kr antibody) Nivolumab + nterleukin-21 Nivolumab + NCB24360 (DO inhibitor) PEMBROLZUMAB carboplatin /paclitaxel, pemetrexed /carboplatin, bevacizumab maintenance, erlotinib, gefitinib or BCG Pembrolizumab and High Dose FN-alfa2b Pembrolizumab +Talimogene Laherparepvec Pf (4-1BB Agonist) NCB (DO inhibitor) Pegylated nterferon Alfa- 2b or pilimumab ADXS (viral vector + PSA) +/- Pembrolizumab Peginterferon Alfa-2b AM0010 (Pegylated L-10) + Pembrolizumab / chemotherapy / pazopanib ic9-gd2 (CAR) T Cell Lymphocytes + Cyclophosphamide + Fludarabine + pembrolizumab PDLZUMAB Pidilizumab + Dendritic Cell renal cell carcinoma vaccine Advanced Solid Tumours 162 Ongoing NCT Solid Tumours 33 Completed NCT Select Advanced Cancers 221 Ongoing NCT Advanced NSCLC 308 Ongoing NCT High Risk Superficial Bladder Cancer Locally/Regionally advanced/recurrent (neoadjuvant) Untreated, Unresected, Stage B to VM1c NCT NCT Ongoing NCT Advanced Solid Tumours 45 Ongoing NCT Selected Solid Tumours 120 Ongoing NCT Advanced (MEL) and Renal Cell Carcinoma Metastatic castrationresistant prostate cancer 343 Ongoing NCT Ongoing NCT Advanced 32 Ongoing NCT Advanced solid tumours 135 Ongoing NCT Relapsed or refractory neuroblastoma Renal Cell Carcinoma Ongoing NCT NCT Sipuleucel +/- pidilizumab Rand. Castration-resistant 57 Ongoing NCT NATURE REVEWS CANCER
4 SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) +/- cyclophosphamide metastatic prostate cancer Multiple myeloma, Pidilizumab + Dendritic following Stem Cell Cell myeloma Vaccine Transplantation MPDL3280A NCB (DO inhibitor) RO (CD40 agonist) MPDL3280A +MOXR0916 (OX40 agonist) or interferonalpha RO (engineered L-2v + antibody against carcinoembryonic antigen) MED4736 MED Gefitinib or AZD9291 or selumetinib + docetaxel or followed by sequential MED4736 Tremelimumab +/- MED4736 ADXS or MED4736 or ADXS MED4736 MED4736 vs vs + MED MED4736 vs MED vs standard of care MED4736 +/- MED Motolimod (TLR-8 agonist) + Pegylated Liposomal Previously Treated Stage B or V Non-Small Cell Lung Cancer Metastatic or locally advanced solid tumours Locally advanced and/or Locally advanced or Locally advanced and/or 35 NCT Ongoing NCT Ongoing NCT NCT Ongoing NCT NCT Non-small cell lung cancer 301 Ongoing NCT Locally advanced or metastatic NSCLC Previously Treated Locally Cervical or HPV+ Head & Neck Cancer Recurrent or Metastatic Recurrent or Metastatic Recurrent gastric or gastroesophageal junction adenocarcinoma Recurrent, Platinum- Resistant Ovarian Cancer 40 Ongoing NCT Ongoing NCT Ongoing NCT NCT NCT Ongoing NCT NCT NATURE REVEWS CANCER
5 SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Doxorubicin Mogamulizumab (anti- CCR4) +MED4736 or MED4736 +AMP-514 (anti-pd-1) MED MED NCB (DO inhibitor) MED Tremelimumab +/- MED4736 Advanced solid tumours 108 Ongoing NCT Advanced Malignancies 160 Ongoing NCT Solid tumours 102 Ongoing NCT Selected advanced solid tumours 157 Ongoing NCT Advanced solid tumours 210 Ongoing NCT Japanese with advanced solid malignancies 22 Ongoing NCT Abbreviations: CAR: chimeric antigen receptor. CCR4; chemokine receptor 4. DO: indoleamine dioxygenase-1. TLR: toll-like receptor. NATURE REVEWS CANCER
Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationWe re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
More informationDevelopment status of OPDIVO (nivolumab) 1
August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationStudies proceeding under pre HRA-Approval system (NHS Permission)
15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL
More informationSupplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
More informationFuture Directions in Immunotherapy
Future Directions in Immunotherapy Naiyer Rizvi, MD Price Chair, Clinical Translational Medicine Director of Thoracic Oncology Director of Immuno-Oncology Columbia University Medical Center New York, New
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationNICE-approved drugs for specialities which fall outside of the services currently provided by the Trust
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationPanaroma da Medicina e Oncologia. Stephen Stefani, MD
Panaroma da Medicina e Oncologia Stephen Stefani, MD Cancer é um problema global 1 em 6 mortes é decorrente de câncer Cancer é a segunda causa de morte Re responsável por 8.8 milhões de mortes por ano
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
More informationSCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:
ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.
More informationDevelopment status of OPDIVO (nivolumab) 1
May 12, 2017 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Non-small cell lung cancer (2 nd ~) Approved Approved Approved *) Non-small
More informationAnnual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
More informationCarla van Herpen Medical Oncologist Immunotherapyin Head & NeckCancer
Carla van Herpen Medical Oncologist 01-10-2016 Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial,
More informationTrial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor
Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03.01.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationDevelopment status of OPDIVO (nivolumab) 1
November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationIntroduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT
PAGE 175 PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT Summary of risk management plan for pembrolizumab This is a summary of the risk management plan (RMP) for pembrolizumab. The RMP details
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationOur Clinical Trials. Oncology
Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine
More informationDevelopment Pipeline Progress Status. February 1, 2019
Development Pipeline Progress Status February 1, 2019 /9 Development status of OPDIVO (nivolumab) (1) Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy)
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationNew Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationSummary... 2 IMMUNOTHERAPY IN CANCER... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 IMMUNOTHERAPY IN CANCER... 3 Sequencing analysis reveals baseline tumour T cell receptor and neo antigen load associates
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationImmuno-oncology combinations: raising the tail of the survival curve
Cancer Biol Med 2016. doi: 10.20892/j.issn.2095-3941.2016.0015 REVIEW Immuno-oncology combinations: raising the tail of the survival curve Samuel J. Harris 1, Jessica Brown 1, Juanita Lopez 1, Timothy
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Décembre 2017 SEIN NEO ADJUVANT WO39392 (Impassion 031) : A phase III randomized study to investigate the efficacy and safety of Atezolizumab in combination
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationYoung Kwang Chae 1,2,3*, Ayush Arya 1, Wade Iams 3, Marcelo R. Cruz 1, Sunandana Chandra 1,2,3, Jaehyuk Choi 2,3 and Francis Giles 1,2,3
Chae et al. Journal for ImmunoTherapy of Cancer (2018) 6:39 https://doi.org/10.1186/s40425-018-0349-3 REVIEW Current landscape and future of dual anti- CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer;
More informationStudienverzeichnis Medizinische Onkologie
Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen
More informationOpdivo (nivolumab) An overview of Opdivo and why it is authorised in the EU. What is Opdivo and what is it used for?
EMA/852560/2018 EMEA/H/C/003985 An overview of Opdivo and why it is authorised in the EU What is Opdivo and what is it used for? Opdivo is a cancer medicine used to treat the following: melanoma, a type
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationChemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationA robust new approach. A rising trend
A robust new approach Since its inception in the mid-0th century, chemotherapy has been the mainstay of cancer treatment and has become increasingly specific and effective. But with the increasing incidence
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More information